Current Two EGFR Mutations in Lung Adenocarcinoma - Case Report

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F15%3A10293949" target="_blank" >RIV/00216208:11150/15:10293949 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11140/15:10293949 RIV/00179906:_____/15:10293949 RIV/00669806:_____/15:10293949
Result on the web
<a href="http://www.prolekare.cz/pdf?id=51850" target="_blank" >http://www.prolekare.cz/pdf?id=51850</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.14735/amko2015134" target="_blank" >10.14735/amko2015134</a>

Result language
angličtina
Original language name
Current Two EGFR Mutations in Lung Adenocarcinoma - Case Report
Original language description
Nowadays, EGFR- TKIs (epidermal growth factor receptor- tyrosine kinase inhibitors) targeted therapy is well established treatment for patients with the so- called EGFR common mutations with advanced or metastatic non-small cell lung cancer. The efficacyfor the so- called rare and especially for the very rare complex EGFR mutations is not clear. We describe a case of a 63- old-year female with metastatic non-small cell lung cancer with complex EGFR mutation (G719X + S768I) who had been treated by gefitinib. She achieved progression free survival within eight months. Then, we discuss our case with other literature case reports. Together, it seems that described complex EGFR mutation has a relatively good sensitivity for EGFR- TKIs treatment.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FC - Pneumology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)